Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q2 2014 · 10-Q
Revenue—
Net Income$194.46K$194.46KN/M vs Q2 2013 EPS Diluted$0.00$0.00N/M vs Q2 2013 Operating Income-$3,508,936N/M Operating Cash Flowderived-$2,951,166N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 13, 2014 · 44 d after period end